Strength Training Response of Muscle in GLP-1 Users
Virginia Polytechnic Institute and State University · NCT07104539
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 50+ · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 30
- US sites recruiting
- 1
- Study start
- October 8, 2025
- Record last updated
- January 21, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
GLP-1 medication is being prescribed for weight loss. However, GLP-1 medication may adversely affect muscle mass and muscle function. Moreover, any loss of muscle mass or muscle function with GLP-1 treatment may impair balance and increase fall risk. This is a particular concern among older adults already susceptible to the common muscle strength and muscle function loss with age, yet there is little evidence among this population. This study will address a gap in knowledge regarding the effects of GLP-1 treatment on muscle mass, muscle function, and balance/fall risk among adults age 50 and older.
Being studied: Strength Training; Wait first, then strength training
Conditions: Muscle Mass
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Age, 50y+
- Be taking GLP-1 medicine (Weygovy or Zepbound) for 1 month or less
- Weight \<300 lb
- Pass a health and exercise readiness screening
Exclusion Criteria
- Age \<50
- Weight >300 lb
- Osteoporosis
- Active metabolic, neoplastic, or cardiovascular disease
- Unable or unwilling to provide consent
Recruiting US locations
Virginia Tech
Blacksburg, VA 24061
Study contacts (from the official record)
- Kevin Davy · 540-231-3487 · kdavy@vt.edu
- Elaina Marinik · 540-231-0923 · emarinik@vt.edu
Similar studies in Virginia
All weight loss studies in Virginia →- RecruitingHealthy volunteersPhase 1/Phase 2
Vaginal Microbiome Seeding and Health Outcomes in Cesarean-delivered Neonates.
National Institute of Allergy and Infectious Diseases (NIAID)
- Location
- Falls Church, VA
- Eligibility basics
- Ages 0 mo–50
- RecruitingHealthy volunteersPhase 3
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Location
- Manassas, VA + 55 other US sites
- Eligibility basics
- Ages 18–79
- RecruitingPhase 2
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
AbbVie
- Location
- Arlington, VA + 58 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes
Novo Nordisk A/S
- Location
- Charlottesville, VA + 13 other US sites
- Eligibility basics
- Ages 10–18